Moleculin to Present at the Virtual Investor Pitch Conference
Moleculin to Present at the Virtual Investor Pitch Conference
Live video webcast on Tuesday, June 18th at 3:00 PM ET
週二，6月18日現場直播th在美國東部時間下午3:00
HOUSTON, June 12, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 3:00 PM ET.
2024年6月12日，休斯頓——莫勒克林生物技術公司HOUSTON，2024年6月12日——Moleculin（Nasdaq: MBRX）（下稱“公司”），一家臨床階段的藥物公司，擁有一系列瞄準難以治療的腫瘤和病毒的藥物候選品，今天宣佈將參加資訊會議，時間爲2024年6月18日下午3:00 PM ET。虛擬投資者路演會議https://www.prnewswire.com/news-releases/moleculin-to-present-at-the-virtual-investor-pitch-conference-302170145.html
As part of the event, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, will provide an "elevator pitch" and outline the Company's upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as possible in the time allowed.
作爲活動的一部分，Moleculin的董事長兼首席執行官沃爾特·克萊普（Walter Klemp）將進行“電梯演講”，並概述公司即將到來的里程碑事件。此外，投資者和其他感興趣的各方將有機會在活動期間實時提交問題。參與公司將在允許的時間內回答儘可能多的問題。
A live video webcast of the event will be available on the Events page under the Investors section of the Company's website (moleculin.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
機器人演示的網絡直播視頻將在公司網站（aimimmuno.com）的“活動”頁面上提供。演示的網絡直播視頻將在現場演示後兩小時提供，並可訪問90天。本次活動的直播將在公司網站的活動頁面下提供。的信息，請訪問aimimmuno.com並與公司聯繫。所有板塊投資者，詳見公司網站（moleculin.com)。演講的網絡直播視頻將在現場演示後兩小時提供，並可訪問90天。
About Moleculin Biotech, Inc.
關於莫勒克林生物技術公司Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. All interim and preliminary data related to its active clinical trials are subject to change.
莫勒克林生物技術公司是一家臨床階段的藥品公司，擁有一個不斷增長的藥物組合，包括第二階段臨床試驗計劃，用於難治性腫瘤和病毒。公司的領先項目安納黴素是一種下一代蒽環類藥物，旨在避免多藥耐藥機制，並消除目前處方蒽環類藥物常見的心臟毒性。安納黴素目前正在開發用於治療復發或難治性急性髓細胞白血病（AML）和軟組織肉瘤（STS）肺轉移病例。與正在進行的臨床試驗相關的所有中期和初步數據都可能會發生變化。
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as certain cancer indications.
此外，公司正在開發WP1066——一種能夠抑制p-STAT3和其他致癌轉錄因子並同時刺激自然免疫反應的免疫/轉錄調節劑，用於治療腦腫瘤、胰腺癌和其他癌症。莫勒克林還致力於開發一系列抗代謝物，包括WP1122，用於潛在的病毒治療，以及某些癌症適應症。
For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.
有關該公司的更多信息，請訪問其官網www.moleculin.com，並關注推特, LinkedIn和頁面。Facebook.
Investor Contact:
投資者聯繫人：
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
JTC團隊有限責任公司
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-present-at-the-virtual-investor-pitch-conference-302170145.html
SOURCE Moleculin Biotech, Inc.
資訊來源：Moleculin生物科技公司。
譯文內容由第三人軟體翻譯。